Shandong Weigao Orthopaedic Device Future Growth
Future criteria checks 4/6
Shandong Weigao Orthopaedic Device is forecast to grow earnings and revenue by 30.4% and 19.3% per annum respectively. EPS is expected to grow by 31.1% per annum. Return on equity is forecast to be 7.7% in 3 years.
Key information
30.4%
Earnings growth rate
31.1%
EPS growth rate
| Medical Equipment earnings growth | 26.3% |
| Revenue growth rate | 19.3% |
| Future return on equity | 7.7% |
| Analyst coverage | Low |
| Last updated | 11 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,036 | 343 | 476 | 343 | 1 |
| 12/31/2025 | 1,762 | 292 | 305 | 292 | 1 |
| 12/31/2024 | 1,474 | 222 | 232 | 222 | 1 |
| 9/30/2024 | 1,284 | 155 | 190 | 216 | N/A |
| 6/30/2024 | 1,229 | 94 | 171 | 206 | N/A |
| 3/31/2024 | 1,242 | 53 | 56 | 101 | N/A |
| 12/31/2023 | 1,284 | 112 | 76 | 119 | N/A |
| 9/30/2023 | 1,594 | 238 | 198 | 237 | N/A |
| 6/30/2023 | 1,654 | 278 | 76 | 115 | N/A |
| 3/31/2023 | 2,060 | 580 | 255 | 361 | N/A |
| 12/31/2022 | 2,058 | 601 | 393 | 509 | N/A |
| 9/30/2022 | 2,129 | 680 | 504 | 631 | N/A |
| 6/30/2022 | 2,268 | 755 | 680 | 832 | N/A |
| 3/31/2022 | 2,120 | 694 | 790 | 906 | N/A |
| 12/31/2021 | 2,154 | 690 | 676 | 788 | N/A |
| 9/30/2021 | 2,133 | 670 | 645 | 745 | N/A |
| 6/30/2021 | 2,087 | 660 | 615 | 690 | N/A |
| 3/31/2021 | 1,958 | 614 | 593 | 636 | N/A |
| 12/31/2020 | 1,824 | 558 | 595 | 644 | N/A |
| 12/31/2019 | 1,574 | 442 | 505 | 534 | N/A |
| 12/31/2018 | 1,211 | 324 | 271 | 324 | N/A |
| 12/31/2017 | 906 | 203 | N/A | 251 | N/A |
| 12/31/2015 | 670 | 220 | N/A | 204 | N/A |
| 12/31/2014 | 602 | 218 | N/A | 192 | N/A |
| 12/31/2013 | 512 | 219 | N/A | 157 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688161's forecast earnings growth (30.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 688161's earnings (30.4% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 688161's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688161's revenue (19.3% per year) is forecast to grow faster than the CN market (13.8% per year).
High Growth Revenue: 688161's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688161's Return on Equity is forecast to be low in 3 years time (7.7%).